ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Clinical Societies, Patient Groups Need New Alliance, Glick Proposes to ASCO

May 24, 1996

NCCN Updates Treatment Guidelines To Include CEF For Early Breast Cancer.

January 26, 2001

St. Jude Considers Relocating to Washington U.

August 9, 1985

Steven Curley Named Chief of Surgical Oncology At Baylor’s Dan L. Duncan Cancer Center

October 4, 2013

NCI CTEP-Approved Trials For the Month of December

December 26, 2014

NCI Test Panels Available For Marker Evaluation

March 2, 1984